Cite
HARVARD Citation
Van den Berghe, N. et al. (2019). Immunogenicity is not the driving force of treatment failure in vedolizumab‐treated inflammatory bowel disease patients. Journal of gastroenterology and hepatology. 34 (7), pp. 1175-1181. [Online].